The effect of coadministration of bupropion (50 mg kg-1, p.o.) on the disposition profile of phenytoin has been studied in the rat. Plasma phenytoin concentration was measured serially for 10 h by HPLC. Bupropion had little or no effect on the pharmacokinetic parameters of an acutely administered dose of phenytoin. Following multiple doses of phenytoin however (i.e. steady state) the coadministration of bupropion resulted in significant increases in the elimination half-life (t 1/2), the area under the plasma concentration-time curve (AUC) and the time to maximum plasma concentration (tmax). Allowing for the limitations of single dose studies, these results point to a possible pharmacokinetic interaction between bupropion and phenytoin--the clinical significance of which needs to be assessed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.2042-7158.1990.tb07025.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of extract on pharmacokinetics of phenytoin in rats.
Nat Prod Res
December 2024
Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.
Epilepsy patients are at a higher risk of developing overweight and obesity. Given the thermogenic properties of (Guarana), this study aimed to evaluate a potential pharmacokinetic interaction between extract and phenytoin in rats. Two pharmacokinetic studies were developed with and phenytoin: a coadministration and a pre-treatment study.
View Article and Find Full Text PDFCombined carbapenem resulted in a 4.48-fold increase in valproic acid clearance: a population pharmacokinetic model in Chinese children and adults with epilepsy or after neurosurgery.
Front Pharmacol
November 2024
Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Our study aims to explore the pharmacokinetics of valproic acid (VPA) in Chinese patients with epilepsy or after neurosurgery and establish a robust population pharmacokinetics (PPK) model. The PPK model was developed using nonlinear mixed-effects modeling, incorporating a total of 615 VPA plasma concentration data points from 443 Chinese epilepsy or after neurosurgery patients. A one-compartment model with an additive residual model was established.
View Article and Find Full Text PDFEvaluating the performance of multi-omics integration: a thyroid toxicity case study.
Arch Toxicol
October 2024
Helmholtz Centre for Environmental Research, UFZ, 04318, Leipzig, Germany.
Article Synopsis
- Multi-omics data integration is a key focus in toxicology for better understanding cellular responses to chemical exposure; the study reviews current practices and provides guidelines for optimal multi-omics research design.
- Despite recognizing the benefits, the researchers found limited availability of comprehensive multi-omics datasets, hindering a full evaluation of the methodologies used in toxicology.
- In their own study on thyroid toxicity, they utilized a multi-omics approach to identify regulatory responses and discovered that integrating multiple omics layers enhances data interpretation and reveals insights into mechanisms like non-coding RNA involvement.
Influence of CYP2C9 phenotypes on phenytoin plasma concentration in neurosurgical Brazilian patients.
Pharmacogenet Genomics
December 2024
Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.
Article Synopsis
- The study examined how different CYP2C9 genetic variants affect phenytoin plasma concentrations in neurosurgical patients in Brazil.
- It involved 170 patients treated with phenytoin post-surgery, with blood samples taken to measure drug levels and assess genetic variations.
- Results showed significant variation in drug levels based on CYP2C9 phenotypes, with poor metabolizers consistently having levels above the therapeutic range, indicating a need for dosage adjustments.
Patient resuscitated after cardiopulmonary arrest exhibits abnormally increased phenytoin metabolic rate due to unknown factors: a case report.
J Pharm Health Care Sci
August 2024
Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8511, Japan.
Background: Fosphenytoin (FOS) is a prodrug of phenytoin (PHT) with a metabolism that exhibits Michaelis-Menten-type kinetics. Genetic polymorphisms of the metabolic enzymes of PHT make it challenging to predict its plasma concentrations. High plasma PHT concentrations are typically problematic, and several causes have been elucidated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!